Clinicians
Individuals & Families
About Us
Contact

Home
/
Knowledge Base (Clinicians)
/
Long-acting Injectables

Tag: Long-acting Injectables

54 result(s) found.

How do you treat akathisia from treatment with long-acting injectable antipsychotics (LAIs)?
Guide to Long-Acting Medications for Providers and Organizations – Reserved for Treatment-Resistant cases?
Long-acting injection antipsychotic medications in the management of schizophrenia (excerpt from APA Clinical Practice Guideline)
Aspiration in injections: Should we continue or abandon the practice?
Long-Acting Injectables: Pharmacological Information – LAI Table of Considerations
When prescribing, what should I consider regarding doses of antipsychotic medications, oral or long-acting injectable medications?
Risperdal Consta/Risperidone for Extended-Release Injectable Suspension
What should clinicians know about Abilify Maintena (aripiprazole monohydrate LAI)?
What should clinicians know about Perseris (risperidone subcutaneous LAI)?
What should clinicians know about Aristada Initio (aripiprazole lauroxil LAI)?
What should clinicians know about Aristada (aripiprazole lauroxil LAI)?
What should clinicians know about haloperidol decanoate (“Haldol Dec”)?
What should clinicians know about fluphenazine decanoate (“Prolixin Dec”)?
What should clinicians know about Invega Trinza (paliperidone palmitate 12-week LAI)?
What long-acting injectable (LAI) antipsychotic medications are available in the U.S.?
What should a provider consider when administering long-acting injectable (LAI) antipsychotics?
What should I consider and how do I change or switch a patient from a different long acting injectable medication (LAI) to Abilify Maintena?
What should clinicians know about Invega Sustenna (paliperidone palmitate LAI)?
What mistakes should providers be aware of when prescribing and administering long-acting injectables (LAIs)?
What are important considerations for the use of long-acting injectable (LAI) antipsychotic medications in first-episode psychosis patients?
What is known about therapeutic drug monitoring (TDM) for antipsychotic medications?
Is there anything that can be done if a patient experiences sedation as a side effect after a long-acting injectable (LAI) deltoid injection?
How do I transition a patient from risperidone oral to paliperidone palmitate (Invega Sustenna) long-acting injectable (LAI)?
What are clinical situations where the use of an oral antipsychotic together with a long-acting injectable (LAI) antipsychotics may make sense?
What are clinical indications for the use of long-acting injectable (LAI) antipsychotics?
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
What is shared decision making and how does it apply to using long-acting injectables (LAIs)?
What can be done if a LAI medication becomes less effective part way through the inter-injection interval?
What should I consider and how do I change or switch a patient from a different long acting injectable (LAI) antipsychotic medication to Aristada?
What should I consider and how do I change or switch a patient from a different long-acting injectable medication (LAI) to Invega Sustenna (paliperidone palmitate)?
What should clinicians know about Zyprexa Relprevv (olanzapine for extended release injectable suspension)?
When should you offer a long-acting injectable (LAI) for first-episode patients?
What are dose conversions from oral to injectable for the long-acting injectable (LAI) antipsychotic medications available in the U.S.?
Long-acting injectable antipsychotics (LAIs) use for older adults
What is recommended for handling waste associated with administration of long-acting injectable antipsychotics (LAIs)?
How do I switch a patient treated with LAI to Risperdal Consta (risperidone microspheres)?
Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness
What do APA’s Schizophrenia Treatment Guidelines say about long-acting injectable antipsychotics?
Antipsychotic Receptor Binding Properties
Guidance for Missed Maintenance Doses for Long Acting Injectable Antipsychotics
What should clinicians know about Invega Hafyera (paliperidone palmitate 6-month LAI)?
Long Acting Injectable (LAI) Antipsychotic Use During Pregnancy
Talking to Individuals and Families About Long-Acting Injectables
What is tardive dyskinesia (TD)?
Antipsychotics and heat-related illnesses
Video: Intramuscular (IM) Injection of Long-acting Injectables into Deltoid Site
Video: Intramuscular (IM) Injection of Long-acting Injectables into Ventral Gluteal (or Ventrogluteal) Site
Video: Intramuscular (IM) Injection of Long-acting Injectables into Dorsal Gluteal (or Dorsogluteal) Site
Video: Subcutaneous (SC) Injection of Long-acting Injectables into Abdominal Site
What should clinicians know about Uzedy (risperidone subcutaneous LAI)?
What should clinicians know about Abilify Asimtufii (aripiprazole LAI)?
What should clinicians know about Brixadi (Subutex)?
What should clinicians know about Vivitrol (Naltrexone)?
What should clinicians know about Sublocade (Suboxone)?

Funding for SMI CalAdviser was made possible by Agreements 24-73017-000 and 24-IT-O0014 from the State of California Department of State Hospitals (DSH) (the Department), but does not necessarily represent the views of the Department or any of its employees except to the extent, if any, that it has formally been approved by the Department.

Sitemap

Clinicians
Individuals & Families
About
Contact
Terms & Privacy

Resources
Education
Centers of Excellence
Copyright

© 2025 American Psychiatric Association. All rights reserved.

(Esc)